Taysha Gene Therapies (NASDAQ:TSHA) Earns “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report report published on Monday morning,Benzinga reports. The firm currently has a $6.00 target price on the stock.

Several other equities analysts have also commented on the stock. Chardan Capital reissued a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Canaccord Genuity Group increased their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Stock Up 6.8 %

Shares of NASDAQ TSHA opened at $2.05 on Monday. The stock has a market capitalization of $420.13 million, a P/E ratio of 3.25 and a beta of 0.95. The stock’s fifty day moving average is $2.10 and its 200 day moving average is $2.15. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51.

Institutional Trading of Taysha Gene Therapies

A number of hedge funds have recently added to or reduced their stakes in the stock. Creative Planning acquired a new position in shares of Taysha Gene Therapies during the third quarter worth $28,000. Principal Financial Group Inc. bought a new stake in Taysha Gene Therapies during the 2nd quarter worth $48,000. China Universal Asset Management Co. Ltd. increased its holdings in Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after purchasing an additional 17,446 shares in the last quarter. Intech Investment Management LLC bought a new position in Taysha Gene Therapies in the third quarter valued at about $85,000. Finally, Scientech Research LLC acquired a new stake in shares of Taysha Gene Therapies during the second quarter valued at about $97,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.